Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness

Inclusion Criteria: Individuals of both sexes that attend the selected schools in the trial areas in Ghana and Kenya that meet the following criteria: 1. Age: 5 to 17 years old (included). 2. Height: over 110 cm. 3. Parental acceptance to participate in the study by obtaining written informed consent approved by the Ethics Committee. Written assent will also be obtained from children according to the local national legislation (12-17 years old). Exclusion Criteria: 4. Epidemiological risk of being infected by Loa loa, defined as those who have visited any of the following countries: Angola, Cameroon, Central Africa Republic, Chad, Congo, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan. 5. Serious medical illness, defined as participants showing symptoms of acute illness which could hamper the participation in the trial, such as high-grade fever, severe diarrhoea, neurological symptoms or others, per investigator's criteria. 6. Any condition prevents the appropriate evaluation and follow-up of the participant, per the investigator's criteria. 7. Known hypersensitivity to any component of either study treatment. 8. Pregnant or first week post-partum: female participants who are post-menarche must have a negative urine pregnancy test at screening.